Additionally, it contributes to cisplatin resistance in hypoxic osteosarcoma cells by directly repressing the tumour suppressor gene PTEN, which activates the PI3K/AKT anti-apoptotic and survival pathways (Table S3) [68]. This evidence concerns the gene AKT1 and osteosarcoma.